Carbiotix announces the launch of its second generation gut heath diagnostic platform
Carbiotix AB (publ) ("Carbiotix") announces today that the company will launch its second generation gut health diagnostics platform in Q1 of 2020. This platform will allow Carbiotix to attain a leading position in the diagnostics area by targeting a global market, which is estimated to be worth 800 million Euro for both consumer and clinical microbiome diagnostic services.
Kristofer Cook, CEO for Carbiotix, comments
“Carbiotix current diagnostic platform for gut health is based on a Fiber Loving Bacteria (FLB) Index, which is a simplified and cost-effective gut health test based on key biomarkers for gut health. This test allowed the company to validate the feasibility and need for repeat & longitudinal sampling to increase the reliability of gut health data. Carbiotix second generation gut health diagnostic platform will build on these cost savings and key learnings, however will also be built on a Next Generation Sequencing (NGS) analytical platform with additional parameters that will allow the company to compete directly with other service providers. This will mean that the company after the launch will target a global market for consumer and clinical microbiome diagnostic services estimated to be worth 800 million Euro annually.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 22 November 2019.
Forward-looking statements This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is a biotechnology company developing Microbiome Modulator Therapeutics that amplify the production of key metabolites for the treatment of different metabolic and chronic diseases. The company’s therapeutics are based on a propriety AXOS soluble fiber, isolated bacterial strains, and innovative formulations, supported by cost effective gut health testing services used to regularly diagnose and monitor gut health, as well as dose therapeutics.